e Carbapenems are considered the treatment of choice for Acinetobacter baumannii infections. Many facilities implement preventive measures toward only carbapenem-resistant A. baumannii (CRAB). However, the independent role of the carbapenem resistance determinant on patient outcomes remains controversial. In a 6-year analysis of adults with A. baumannii bloodstream infection (BSI), the outcomes of 149 CRAB isolates were compared to those of 91 patients with carbapenem-susceptible A. baumannii. In bivariable analyses, CRAB BSIs were significantly associated with worse outcomes and with a delay in the initiation of appropriate antimicrobial therapy (DAAT). However, in multivariable analyses, carbapenem resistance status was no longer associated with poor outcomes, while DAAT remained an independent predictor. The epidemiological significance of A. baumannii should not be determined by its resistance to carbapenems.
A
cinetobacter baumannii is one of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens (1), which result in a variety of serious infectious clinical syndromes (2) (3) (4) . Apart from a continuous increment in incidence, offending human strains have also become more resistant (5) . The prevalence of the extensively drug-resistant (XDR) A. baumannii phenotype (6) has increased exponentially worldwide (5, 7, 8) .
Carbapenems are considered the agents of choice for treating A. baumannii infections, as long as the isolates are susceptible (4, 9, 10) . Therefore, resistance to carbapenems frequently determines the epidemiological significance of the pathogen (2, 10) . Many hospitals utilize infection control preventive measures (isolation precautions, cohorting, and screening for asymptomatic carriage), targeting only patients with carbapenem-resistant A. baumannii (CRAB) strains (11) . However, both molecular epidemiology and clinical epidemiology investigations do not support these practices. Many of the mechanisms of resistance to carbapenems are chromosomally encoded (12) . Therefore, it might be appropriate to target the prevention of patient-to-patient transmission of all A. baumannii isolates, since even susceptible organisms might become resistant after they are acquired by a new host. Moreover, controlled clinical data correlating resistance to carbapenems with worse patient outcomes were subjected to several biases, i.e., the majority of studies had low sample size, infection was not appropriately differentiated from colonization, and most studies did not control for time to initiation of appropriate antimicrobial therapy (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Delay in initiating appropriate antimicrobial therapy (DAAT) is the strongest modifiable predictor of worse outcomes among septic patients (23, 24) , and DAAT has frequently been reported in A. baumannii infections (25) . Therefore, the aim of this study was to explore the independent role of the carbapenem resistance phenotype on the clinical outcomes of patients truly infected (i.e., those with bloodstream infections) with A. baumannii.
A retrospective cohort study was conducted at the Assaf Harofeh Medical Center (AHMC), Israel. Adult patients (Ն18 years) with a positive blood culture of A. baumannii, coupled with systemic inflammatory response syndrome (SIRS) (26) , were enrolled from January 2007 to December 2012. Only the first BSI episode for each patient was included in the final analysis. During the study years, the Vitek-2 (bioMérieux, France) automated system was used at AHMC to diagnose A. baumannii infection and determine its antibiotic susceptibilities. Representative isolates were confirmed by 16S rRNA, 16S-23S internal transcribed spacer (ITS), and rpoB and gyrB sequencing. The local Helsinki committee at AHMC approved the study prior to its initiation. A patient was defined as a case (i.e., CRAB) if its causative A. baumannii blood isolate was nonsusceptible to Ն1 group 2 carbapenem. Data were extracted from all available records, and posthospitalization mortality data were captured from a national registry. Each outcome was separately analyzed. A risk factor analysis for being a CRAB case (versus carbapenem-susceptible A. baumannii [CSAB] ) was conducted as well. This was not a matched case-case-control investigation, and therefore this analysis was not aimed to study CRAB predictors but was conducted in order to investigate the exact features of being a CRAB case that might impact the outcomes of patients. Multivariable models for each outcome were constructed using Cox regression. In all models, the carbapenem resistance status was forced into the model (the case parameter). The association between being a CRAB case and the outcome of interest was assessed with and without the addition of DAAT. Final multivariable models included only variables that remained independently associated with the outcome of interest (P Յ 0.05). Since in polymicrobial infections, the pathognomonic role of A. baumannii is debatable (2), even in BSIs (2, 10), a subanalysis of monomicrobial isolations only (i.e., only A. baumannii grew from all of the blood cultures taken on the index culture date) was conducted in order to assess the correlation between carbapenem resistance in monomicrobial A. baumannii BSI and clinical outcomes. Survival analysis was executed by using the Kaplan-Meier curve and the log rank test for significance.
Two hundred forty adult patients with unique episodes of A. baumannii BSI between 2007 and 2012 were enrolled; 149 (62%) patients had CRAB, and 91 (38%) had carbapenem-susceptible A. baumannii BSI (CSAB). The median age of the patients was 80 years (interquartile range [IQR], 66.5 to 84.7 years), and 109 patients (45%) were Ͼ65 years. Nearly 75% of the patients were functionally dependent prior to infection, 48% were cognitively impaired, 88% had recent invasive procedure, and 79% had a permanent invasive foreign device. The mean Ϯ standard deviation (SD) Charlson's combined condition score was 6.3 Ϯ 2.8 (27) , and 44% of the patients were immunosuppressed. In terms of illness acuity indices, the mean Ϯ SD Pitt bacteremia score was 5.4 Ϯ 3.7 (28), 43% of the patients had a rapidly fatal condition (29) , and 37% of the patients necessitated acute mechanical intubation. Pneumonia was the origin for 56% of BSI cases, and 16% had primary BSI (30) . The vast majority of patients (89%) had recent (within 3 months) exposure to antibiotics, and the median delay in instituting appropriate antimicrobial therapy was 47 h.
Following bivariable analysis (data not shown), the variables that were inserted into the multivariable model that differentiate CRAB BSI from CSAB BSI included: past recent invasive procedure, permanent foreign device, recent prior exposure to all antibiotics, recent prior exposure specifically to carbapenems, rapidly fatal McCabe condition (29) , time at risk (i.e., days from admission to culture), Pitt bacteremia score (28) , and number of recent prior antibiotics administered. After modeling, the independent significant features of CRAB BSIs were (i) permanent foreign invasive devices (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.1 to 4.8; P ϭ 0.03), (ii) recent prior (within 90 days) carbapenem therapy (OR, 2.5; 95% CI, 1.3 to 5.1; P ϭ 0.01), and (iii) a rapidly fatal McCabe condition score (29) (OR, 2.1; 95% CI, 1.1 to 3.8; P ϭ 0.02).
In terms of clinical outcomes, 146 patients (60.8%) died during the index hospitalization, 138 (57.5%) patients died within 30 days, and 157 patients (65.4%) died within 90 days. Table 1 summarizes the analyses of the relationship between CRAB and the clinical outcomes, as well as the correlation between CRAB and the administration of appropriate antimicrobial therapy. CRAB BSIs were strongly and significantly associated with worse clinical outcomes compared to those of CSAB BSIs in the bivariable analyses. In addition, patients with CRAB BSIs were prone to experiencing DAAT. In order to study whether the worse outcomes associated with CRAB were related to DAAT, additional intrinsic properties of the organisms, and/or patient characteristics, we conducted separate bivariable and multivariable analyses for each outcome. Table 2 summarizes the final model for each of these outcomes. As displayed in Table 2 , CRAB was no longer significantly associated with any one of the outcomes, apart from extended length of hospital stay (LOS) after isolation (excluding the patients who died). The administration of appropriate therapy was significantly and independently associated with the majority of the studied outcomes.
As explained in the Materials and Methods, we also constructed a separate subanalysis of monomicrobial isolations only (52% of A. baumannii BSIs). The correlation between monomicrobial isolation of CRAB and worse clinical outcomes and DAAT in these analyses was less clear. There was still a statistically significant (yet weaker) correlation between CRAB and higher rates of in-hospital mortality and extended LOS after A. baumannii monomicrobial isolation. In multivariable analyses, monomicrobial isolation of CRAB (versus CSAB) was also not independently associated with worse outcomes (data not shown).
A Kaplan-Meier survival analysis was also generated in order to illustrate the 1-year survival rates of patients with CRAB versus CSAB BSI (Fig. 1) . The mean Ϯ SD survival time was less for CRAB BSI patients than for CSAB BSI patients (26.6 Ϯ 5.4 days versus 47.9 Ϯ 9.2 days, respectively; P ϭ 0.018).
To summarize, since many practitioners determine the epidemiological significance of A. baumannii based on its carbapenem resistance status, we conducted this detailed controlled comprehensive investigation in order to test these practices. Many hospitals implement contact isolation precautions (CIP) only when A. baumannii carriers harbor a CRAB isolate. Other hospitals have screening policies aimed at identifying asymptomatic carriers of CRAB but not of CSAB (31) . However, A. baumannii can rapidly convert from CSAB to CRAB in response to certain stressors (12) . Based on these analyses, we propose that CIP and all other preventive measures should be instituted to curb rates of patient-topatient transmission of all A. baumannii isolates, regardless of the resistance status to carbapenems.
In this cohort study, the largest of its type, to our knowledge, only patients with BSI (i.e., bacteremia coupled with SIRS [26] ) were enrolled, since it is sometimes difficult to determine the carriage status with isolations of A. baumannii from other sources. Our cohort consisted of elderly sick individuals with multiple exposures to health care settings and antibiotics. Patients with CRAB had functional status and comorbidities on admission similar to those of patients with CSAB, but patients with CRAB, per bivariable analyses (Table 1) , suffered from significantly worse outcomes and DAAT. However, in the multivariable analyses (Table  2) , the carbapenem resistance phenotypic determinant did not remain a significant predictor for any of the captured outcomes, apart from extended LOS. In prior comparative analyses, outcomes associated with CRAB were independently worse than outcomes associated with CSAB (19); however, these studies did not appropriately control for parameters quantifying the delay in the initiation of antimicrobial therapy (DAAT) and did not implement strict case definitions for infection. In our subanalysis of monomicrobial isolations, the associations between carbapenem resistance and clinical outcome became even weaker. We believe all this implies that carbapenem resistance is not independently associated with worse clinical outcomes among patients with true A. baumannii infection. The only outcome that remained independently associated with carbapenem resistance was an extended LOS, which constitutes mainly (but not only) a cost parameter. In the composite direct cost analysis, however, CRAB isolates were not independently associated with increased fiscal burden (data not shown). This implies that the epidemiological significance of A. baumannii isolations in hospitals should not be based on the carbapenem resistance status of the offending isolate.
Although this was not a matched case-case-control investigation, one of the independent significant 'predictors of CRAB isolation (and not CSAB isolation) was recent prior exposure to carbapenems. As previously detailed, since many of the resistance mechanisms to carbapenems in A. baumannii are chromosomally encoded, the exposure to carbapenems specifically might result in conditions favoring the transition of isolates from CSAB to CRAB (12, 20) . However, many other antimicrobials, per bivariable analyses, were associated with CRAB but not CSAB (e.g., aminoglycosides and ␤-lactam-␤-lactamase inhibitor combinations). Only an ecological investigation, using longitudinal time series analysis, could explore the exact role of the specified exposure to carbapenems on the emergence of resistance to carbapenems among A. baumannii offending strains (32, 33) .
To conclude, we believe this study demonstrates that the clinical significance of A. baumannii bloodstream infection was not related to the carbapenem resistance status. The single-center and retrospective chart review-based design can pose multiple inherent biases, but the large cohort of 240 patients with BSIs might dilute some of these biases. These same results were recently reported from (much) smaller cohort studies worldwide, e.g., in Korea, Taiwan, Greece, and the United States (14) (15) (16) 24) . Regardless of strain, in order to improve the outcomes of patients with A. baumannii BSIs, efforts should be directed at reducing DAAT by using innovative modalities (e.g., rapid diagnostics and prediction tools). In addition, tight and strict adherence to both antimicrobial stewardship recommendations and infection control measures to reduce the emergence of resistance to carbapenems and patient-to-patient transmission of A. baumannii strains, respectively, are of paramount importance.
